Use of first-line (1L) OPDIVO® (nivolumab) in combination with low-dose YERVOY® (ipilimumab) in certain patients with metastatic NSCLC with PD‑L1 expression ≥1%

The Lynx Group: 2021 Ask The Expert MDietrich.pdf
Please Click the Issue to Download

Introduction

This resource provides insights and guidance by a thought leader into frequently asked questions on the open-label, phase 3, Checkmate 227 study evaluating the use of 1L nivolumab in combination with low-dose ipilimumab in patients with metastatic NSCLC and PD-L1 ≥1%.

Download to Continue Reading

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: